Physicians are "very satisfied" with Santarus' (SNTS +0.4%) Uceris a survey conducted by Stifel...


Physicians are "very satisfied" with Santarus' (SNTS +0.4%) Uceris a survey conducted by Stifel Nicolaus (Buy, PT raised to $24 from $22) shows. Analyst Annabel Samimy also notes that gastroenterologists seem to be comfortable prescribing the drug for several off-label indications as well, supporting recent "anecdotal reports." SA contributor Oneil Trader thinks the shares have "room to more than double in the next couple of years."

Comments (1)
  • laver
    , contributor
    Comments (12) | Send Message
     
    Thirty years in the market tells me this horse has just begun to run. As Cramer says, Buy! Buy! Buy!
    11 Jun 2013, 12:18 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs